All In MedTech

Device Trial Radar · NCT07931534

Pediatric Adeno-Tonsillar Hypertrophy Treatment Post-Approval Study

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

73

Planned (sponsor's estimate)

Start

Nov 5, 2026

Primary completion

May 6, 2028

Study completion May 6, 2028

Sponsor

Lead sponsor
ENTire Medical Ltd.Not on our public-company list
Sponsor type
Industry
First posted
Nov 12, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, multi-center, single-arm study of pediatric subjects (age 3-12) with Sleep-Disordered Breathing ("SDB") due to adeno-tonsillar hypertrophy which are treated with the ENTire IRE System. Subjects will be followed for six (6) months post-treatment. The objective of the study is to provide an ongoing safety and effectiveness assessment of the ENTire IRE System in treating pediatric adeno-tonsillar hypertrophy.

Conditions

  • Airway Obstruction Upper
  • Tonsillectomy
  • Adenoidectomy Surgery
  • Hypertrophy

Interventions

  • Irreversible ElectroporationDevice

    The bi-polar IRE System locally applies short, high-voltage (HV) pulses, increasing the permeability of tissue cells, creating non-thermal irreversible electroporation (NTIRE). The energy is transferred via bipolar forceps handpiece causing irreversible cell membrane perforation and apoptosis resulting in tissue reduction. The clinical effect is anticipated within 2 to 4 weeks post-treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Device- or Procedure-Related Adverse Events (Bleeding, Readmission, Dehydration, or Emergency Department Visit)Time frame: 6 months
  2. Time From Treatment to First Wong-Baker FACES Pain Scale Score of 2 or BelowTime frame: From procedure until the end of the first week post procedure (7 days)
  3. Change From Baseline in OSA-18 Total Score at 3 MonthsTime frame: 3 months post treatment

1 more outcomes with a free account

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Colorado

    Denver, Colorado

  • UT Southwestern Medical Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.